FLT3 and acute myeloid leukemia: In AML cells, higher mTORC1 activity and FLT3-ITD-mediated signaling contribute to the continuance of glycolysis and leukemic cells survival and therefore, render therapeutic sensitivity to glycolytic inhibition (Figure 1) (56, 57).